StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH – Free Report) in a report issued on Wednesday morning. The firm issued a sell rating on the stock.
Separately, Roth Mkm restated a “buy” rating and set a $20.00 target price on shares of Bio-Path in a report on Monday, July 8th.
View Our Latest Stock Analysis on BPTH
Bio-Path Trading Up 2.8 %
Bio-Path (NASDAQ:BPTH – Get Free Report) last posted its earnings results on Thursday, August 15th. The company reported ($1.16) earnings per share for the quarter, beating the consensus estimate of ($1.54) by $0.38. During the same quarter in the previous year, the company earned ($10.60) EPS. As a group, research analysts anticipate that Bio-Path will post -6.2 EPS for the current year.
Institutional Investors Weigh In On Bio-Path
An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC purchased a new stake in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH – Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned approximately 4.66% of Bio-Path as of its most recent SEC filing. Hedge funds and other institutional investors own 5.74% of the company’s stock.
Bio-Path Company Profile
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Featured Stories
- Five stocks we like better than Bio-Path
- High Flyers: 3 Natural Gas Stocks for March 2022
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Most active stocks: Dollar volume vs share volume
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Which Wall Street Analysts are the Most Accurate?
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.